<code id='4E6A28D687'></code><style id='4E6A28D687'></style>
    • <acronym id='4E6A28D687'></acronym>
      <center id='4E6A28D687'><center id='4E6A28D687'><tfoot id='4E6A28D687'></tfoot></center><abbr id='4E6A28D687'><dir id='4E6A28D687'><tfoot id='4E6A28D687'></tfoot><noframes id='4E6A28D687'>

    • <optgroup id='4E6A28D687'><strike id='4E6A28D687'><sup id='4E6A28D687'></sup></strike><code id='4E6A28D687'></code></optgroup>
        1. <b id='4E6A28D687'><label id='4E6A28D687'><select id='4E6A28D687'><dt id='4E6A28D687'><span id='4E6A28D687'></span></dt></select></label></b><u id='4E6A28D687'></u>
          <i id='4E6A28D687'><strike id='4E6A28D687'><tt id='4E6A28D687'><pre id='4E6A28D687'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:hotspot    - browse:242
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus